WuXi Biologics Honored with CDMO Management Awards for Ninth Consecutive Yr

SHANGHAI, March 30, 2026 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a number one world Contract Analysis, Improvement and Manufacturing Group (CRDMO), introduced that it has gained “Biologics CDMO of the Yr” (Massive CDMOs) within the 2026 CDMO Management Awards. The corporate has additionally been acknowledged for excellence throughout a number of classes for “Massive CDMO Biologic”, together with “Finest Scaling Assist”, “Finest Analytical Companies”, “Finest General Workers”, and “Finest Venture Administration”. These achievements mark WuXi Biologics’ ninth consecutive 12 months profitable the CDMO Management Awards, underscoring its dedication to advancing built-in expertise platforms that speed up biologics discovery, improvement, and manufacturing. Dr. Chris Chen, CEO of…